Background. Reconstitution of human cytomegalovirus (HCMV) T cell-specific immunity is of crucial relevance in patients receiving a hematopoietic stem cell transplant (HSCT). Scarce data on this subject are available for children receiving a T cell-depleted HSCT.
Hematopoietic stem cell transplantation (HSCT) is an established treatment for many young patients affected by either malignant or nonmalignant disorders. In children lacking a suitable HLA-matched donor (either related or unrelated), recourse to using an HLAhaploidentical relative as a donor often represents the only available option [1] . However, to overcome the risk of life-threatening graft-versus-host disease (GVHD) and graft rejection associated with the high degree of HLA disparity in the donor/recipient pair, the combination of infusion of high doses of hematopoietic stem cells and profound T cell depletion is crucial for patients to have a successful outcome [2] .
Fatal infections occur with increased frequency in patients given a T cell-depleted transplant from an HLAdisparate relative, because, in this case, the recipient cannot benefit from the contribution of adoptively transferred memory T cells [1] [2] [3] . Among the agents causing opportunistic infections that affect the outcome for HSCT recipients, human cytomegalovirus (HCMV) remains one of the most important pathogens [4] . The adoption of strategies of either prophylactic or preemptive treatment has significantly reduced the morbidity and mortality associated with HCMV infection, in particular in recipients of an unmanipulated graft [5, 6] .
However, despite the availability of effective anti-HCMV drugs capable of controlling infections, only after reconstitution of virus-specific T cell immunity does a patient who receives a hematopoietic stem cell transplant (HSCT) acquire robust and sustained protection against HCMV infection and disease [7] [8] [9] .
In recent years, the recovery of HCMV-specific immunity after HSCT has been studied thanks to the availability of techniques allowing assessment of the virus-specific T cell memory response, such as tetramer staining, and intra-or extracellular detection of cytokine production [10, 11] . Although these studies have been mainly performed in adults receiving transplants from HLA-matched donors [12] [13] [14] , no study has specifically addressed the kinetics of HCMV infection and HCMV-specific T cell reconstitution in a large population of children receiving a T cell-depleted HSCT from an HLA-haploidentical family donor.
Recently, we developed a methodologic approach permitting a comprehensive evaluation of the HCMV-specific T cell immune response [15, 16] . This technique was used to study HCMV-specific T cell reconstitution in children receiving HSCT, mainly from an HLA-matched donor and without any manipulation of the graft [17] . In the present study, we used the same method to investigate, in a population of children given a T cell-depleted HSCT from a haploidentical relative, the development of virus-specific T cell immunity, with the aim of better defining the kinetics of T cell reconstitution and its correlation with protection from HCMV infection.
PATIENTS AND METHODS

Patients.
A total of 48 young patients (median age, 8 years; range, 2-25 years) who received a T cell-depleted, allogeneic HSCT from an HLA-disparate relative from July 2003 through September 2007 were included in the study. Twelve of these children were previously described elsewhere [17] .
All patients were given a full-intensity, myeloablative preparative regimen. Peripheral blood CD34 ϩ progenitor cells were mobilized in the donor by administration of granulocyte colony-stimulating factor and were collected using the CliniMacs 1-step procedure (Miltenyi Biotech), which led to depletion of a median of 4 log 10 T cells. Rabbit antithymocyte globulin (3.75 mg/kg/day given from day Ϫ4 to day Ϫ2) was given to all patients before transplantation. Patients experiencing acute or chronic GVHD [18, 19] were treated with steroids alone or in combination with cyclosporin A or tacrolimus as first-line therapy, whereas patients with steroid-resistant disease were treated with extracorporeal photochemotherapy [20] . The characteristics of the patients are presented in table 1. For comparison, 50 children who received an unmanipulated HSCT during the same period were also analyzed. These 50 patients received pharmacologic immunosuppression for GVHD prophylaxis, including cyclosporin A with or without either methotrexate or steroids.
The study was approved by the ethics committee of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, and the patients or their parents/legal guardian provided written, informed consent before the patients entered the study.
Virologic follow-up. HCMV infection was defined by the detection of HCMV in blood by use of any assay, in the absence of clinical manifestations or organ-function abnormalities, whereas HCMV disease was defined by the detection of either systemic or local HCMV infection, in the presence of clinical symptoms and/or organ-function abnormalities [21] . HCMV infection was diagnosed on the basis of either antigenemia (for children receiving an HSCT before March 2007) or DNAemia (for patients who received a transplant after March 2007), according to methods described elsewhere [22, 23] . Patients were preemptively treated when 2 pp65-positive leukocytes/200,000 leukocytes were detected (or at the time when a single positive cell was detected twice 2-3 days apart) or when a cutoff level of 10,000 DNA copies/mL of whole blood was reached [24] . Preemptive therapy was based on intravenous administration of ganciclovir (5 mg/kg twice a day), which was replaced by foscarnet (90 mg/kg twice a day) for cases of ganciclovir-induced neutropenia (defined as Ͻ0.5 ϫ 10 9 neutrophils/L), or a sustained increase in HCMV levels in the blood during receipt of ganciclovir therapy. Antiviral treatment was stopped when virus had been cleared from the blood according to the guiding assay (i.e., after 2 consecutive negative results were noted). Relapses were treated similarly.
Donor/recipient HCMV serologic findings were evaluated using ELISA (ETI-Cytok-G Plus; DiaSorin), according to a method reported elsewhere [25] ; in a subgroup of patients, serum neutralizing antibody was tested on both fibroblasts and endothelial cells, to assess passive antibody transfer, which was revealed by a lack of neutralizing antibody on fibroblasts and by detection of low titers (Ͻ1:160) on endothelial cells [26] .
Immunologic follow-up. Immunologic reconstitution was investigated at 30, 60, 90, 180, and 360 days after transplantation (unless transplant rejection or relapse of the underlying disease occurred). The lymphocytes of the patients were tested to evaluate the frequency of HCMV-specific CD4 ϩ and CD8 ϩ T cells producing interferon (IFN)-␥, by means of cytokine flow cytometry performed after in vitro stimulation with autologous, monocyte-derived, HCMV-infected dendritic cells, as described in detail elsewhere [15] . Absolute CD3 ϩ CD4 ϩ and CD3 ϩ CD8 ϩ T cell counts were determined in heparinized peripheral blood samples by means of direct immunofluorescence flow cytometry (Beckman Coulter). The total number of HCMV-specific CD4 ϩ and CD8 ϩ T cells was calculated by multiplying the percentages of HCMV-specific T cells producing IFN-␥ by the relevant absolute CD4 ϩ and CD8 ϩ T cell count. On the basis of results obtained by testing 46
HCMV-seropositive and 8 HCMV-seronegative healthy blood donors, subjects with an HCMV-specific CD4 ϩ or CD8 ϩ T cell count of Ͼ0.4 cells/L of blood were considered to be immune [15] . In patients receiving HSCT, levels of at least 1 CD4 ϩ and 3 CD8 ϩ HCMV-specific T cells/L of blood were considered to be protective [17] . Statistical analysis. The Mann-Whitney U test was used to compare median values between different groups of patients, whereas Fisher's exact test was used to compare percentages between groups.
The probabilities of developing HCMV infection and an HCMV-specific immune response during the first year after transplantation, as well as the incidences of transplantationrelated mortality (TRM) and GVHD, were calculated and expressed as cumulative incidences, with competing risks taken into account [27, 28] . Differences between groups were compared using the Gray test or the log-rank test, as appropriate. The Cox proportional hazard regression model was used to analyze factors potentially interfering with specific T cell recovery. The following variables were considered: (1) patient characteristics (sex, HCMV serologic findings, age at transplantation, mismatch in the sex of the donor and patient, and alloreactivity of the NK cells of the donor toward the recipient), (2) disease characteristics (e.g., malignant disorders vs. nonmalignant diseases and the time from diagnosis to HSCT), and (3) transplant characteristics (e.g., the total number of CD34 ϩ cells and CD3 ϩ cells infused per kilogram of body weight, the conditioning regimen used [a regimen containing total body irradiation vs. chemotherapy alone], and occurrence of grade II-III acute GVHD and chronic GVHD).
RESULTS
Identification of patients with previous HCMV infection.
As assessed by pretransplantation determination of HCMVspecific IgG serum antibody levels by use of ELISA, 16 patients were found to be HCMV seronegative, and 32 were found to be HCMV seropositive. However, because patients previously received transfusions of blood products or administration of immunoglobulin, the presence of HCMV-specific IgG could be the result of passive transfer. Eleven patients with a low HCMVspecific IgG level (Ͻ1.5 IU/mL), as determined by ELISA, were tested for the presence of serum neutralizing antibody on both fibroblasts and endothelial cells, to assess HCMV infection before transplantation. HCMV-neutralizing antibodies were detected on both fibroblasts and endothelial cells in only 2 of 11 patients, thereby identifying those 2 patients as having a "trueseropositive" finding, whereas, in the remaining 9 patients, absence of neutralizing activity on fibroblasts and a low serum anti-HCMV IgG titer on endothelial cells (Ͻ1:160) were considered to result from passive administration. Thus, 23 patients were considered to have a true HCMV-seropositive finding, and 25 were considered to have a true HCMV seronegative finding (16 were seronegative and 9 were considered to have a false seropositive finding, according to ELISA). HCMV infection and T cell immune reconstitution. Of the 25 HCMV-seronegative HSCT recipients, only one patient developed HCMV infection with the subsequent appearance of HCMV-specific T cells at day 123, whereas another child had virus-specific T cells emerge at day 328, in the absence of detectable HCMV infection in the blood. In this group of patients, the 1-year cumulative incidence of HCMV infection and HCMVspecific immunity was 4% (95% confidence interval [CI], 1%-27%) and 8% (95% CI, 2%-31%), respectively.
Conversely, the 1-year cumulative incidence of HCMV infection among the 23 patients with HCMV infection before transplantation was 83% (95% CI, 68%-100%) (figure 1A). In detail, HCMV infection was diagnosed in 19 patients after a median of 24 days (range, 7-122 days) after transplantation, whereas 4 patients remained HCMV free (table 2). Preemptive therapy was administered to 15 of 19 HCMV-infected patients (4 patients did not reach the cutoff for preemptive therapy) for a median of 39 days (range, 10 -147 days). Only one patient (patient 20) developed HCMV disease (polyradiculoneuritis), which resolved with antiviral treatment and after specific T cell immune reconstitution.
Emergence of HCMV-specific CD4 ϩ and CD8 ϩ T cells was observed in 19 of the 23 patients who had a true-seropositive finding at a median of 72 days (range, 33-223 days) after transplantation. The probability of developing HCMV-specific T cell immunity within 1 year after HSCT was also 83% (95% CI, 68%-100%) (figure 1A). In most (i.e., in 15 of 19) patients, both HCMV-specific CD4 ϩ and CD8 ϩ T cells were detected simultaneously, whereas, in 3 patients, the appearance of specific CD8 ϩ T cells preceded the detection of CD4 ϩ T cells by 1-3 months. In an additional case, HCMV-specific CD4 ϩ T cells were detected 1 month before CD8 ϩ T cells were detected. Immunologic follow-up was not completed for 2 patients (patients 1 and 2), one of whom died and the other of whom had a relapse before both HCMV infection and T cell reconstitution occurred. In 2 other patients (patients 3 and 4), follow-up was discontinued at the time of disease recurrence in the presence of active HCMV infection in blood, which was successfully treated with antiviral agents (table 2). In both of these patients, T cell recovery had not occurred at the time of relapse. The total number of CD4 ϩ and CD8 ϩ T cells, although comparable until day 90, started to be significantly higher (P Ͻ .05) in HCMV-seropositive patients than in HCMV-seronegative patients beginning at day 90. At 1 year after transplantation, the numbers of CD4 ϩ T cells present in HCMV-seronegative HSCT recipients reached the numbers noted in HCMV-seropositive patients, whereas the CD8 ϩ T cell count still remained significantly more elevated in HCMV-seropositive patients ( figure 1C  and 1D ). The 1-year cumulative incidence of TRM did not differ between HCMV-seropositive children (9%; 95% CI, 2%-33%) and HCMV-seronegative children (8%; 95% CI, 2%-30%) (P ϭ .54). In addition, the cumulative incidence of grade II-III acute GVHD was 30% (95% CI, 16%-56%) in HCMVseropositive patients and 16% (95% CI, 7%-39%) in HCMVseronegative patients (P ϭ .25).
Reconstitution of HCMV-specific T cells in recipients of T cell-depleted versus unmanipulated HSCTs. HCMV-specific T cell reconstitution in the 23 HCMV-seropositive recipients of a T cell-depleted HSCT was compared with that in 50 HCMV-seropositive pediatric recipients of an unmanipu-
Figure 1. Human cytomegalovirus (HCMV) infection and T cell reconstitution in children receiving hematopoietic stem cell transplantation (HSCT). Cumulative incidence curves for HCMV infection and HCMV-specific CD8 ϩ and CD4 ϩ T cell reconstitution in 23 HCMV-seropositive children receiving a T cell-depleted (TCD) HSCT (A) and in 50 HCMV-seropositive children receiving an unmanipulated HSCT (B). The total CD4
ϩ and CD8 ϩ T cell counts of seropositive and seronegative recipients of a TCD graft at different times after HSCT are shown in panels C and D, respectively. lated HSCT ( figure 1A and 1B) . Compared with this latter cohort, children receiving T cell-depleted transplants demonstrated significant delayed HCMV-specific T cell reconstitution (median time to reconstitution, 75 vs. 47 days; P Ͻ .01), and the probability of reconstituting HCMV-specific T cells within the first 3 months after transplantation was 61% (95% CI, 44%-84%) for patients receiving a T cell-depleted graft versus 84% (95% CI, 66%-100%) for those receiving an unmanipulated graft (P ϭ .04). Moreover, although the curves relevant to the kinetics of both HCMV infection and HCMVspecific T cell reconstitution were overlapping in children receiving an unmanipulated HSCT (figure 1B), children receiving a T cell-depleted HSCT experienced a median delay of 47 days for specific T cell development with respect to the onset of HCMV infection ( figure 1A) .
HCMV-specific T cell reconstitution and control of viral infection. In a previous study in children, most of whom received an unmanipulated graft, the presence of 1 CD4 ϩ and 3
CD8
ϩ HCMV-specific T cells/L of blood was associated with protection from subsequent relapses of HCMV infection [17] . These T cell levels were observed in the majority (n ϭ 12) of the 19 patients experiencing reconstitution of specific immunity during follow-up simultaneous to the first detection of HCMVspecific T cells and in the remaining 7 patients 1 month later. As shown in figure 2 , the 8 patients in the present study who experienced a self-resolving HCMV infection or no infection at all had faster development of protective immunity than did the 15 patients requiring preemptive therapy (median time, 70 vs. 139 days; P Ͻ .01). After development of protective HCMV-specific T cell immunity, relapses of HCMV infection were observed in 9 (47%) of 19 patients. Of these patients, 6 had spontaneous resolution of the infection, and only 3 (16%) required preemptive therapy. In detail, 1 of these 3 patients (patient 21) had grade III acute GVHD requiring treatment with steroids. This led to a dramatic decrease in total and specific numbers of T cell numbers, fol- Human cytomegalovirus (HCMV) infection development and T cell reconstitution in, as well as the outcome for, 23  HCMV-seropositive patients given a T cell-depleted hematopoietic stem cell transplantation (HSCT lowed by HCMV relapse requiring preemptive therapy. The other 2 patients (patients 22 and 23) had a relapse of HCMV infection after development of chronic GVHD, which was treated with steroids (see also table 2, for further details). In these 2 patients, numbers of HCMV-specific T cell apparently were not modified by steroid treatment.
Factors influencing the reconstitution of HCMV-specific CD4 ؉ and CD8
؉ T cells. Of the factors analyzed to evaluate their possible role in the recovery of the HCMV-specific T cellmediated immune response, the only factor found to significantly influence the recovery of HCMV-specific T cells was the number of residual T cells in the graft (probability ratio, 6.97) (P ϭ .02) for patients receiving Ͼ1 ϫ 10 4 T cells/kg. In addition, there was a trend toward a better recovery for patients Ͻ8 years of age, with a probability ratio of 4.57 (P ϭ .07) ( figure 3 ). There was no correlation between the age of the patient and the number of T cells that the patients received (P ϭ .9; R 2 ϭ 0.0001).
DISCUSSION
In the present study, HCMV infection and virus-specific T cell recovery were investigated in young patients receiving a T celldepleted HSCT from an HLA-haploidentical donor. The results were compared with those of children receiving unmanipulated HSCT from an HLA-matched sibling or unrelated donor. The methodology used for investigation of HCMV-specific T cell reconstitution provides a comprehensive assessment of the virusspecific T cell pool, regardless of epitope specificity and patient HLA typing [15, 16] . The major findings of the present study include the following: (1) development of HCMV-specific T cells depends mostly on pretransplantation HCMV infection of the recipient; (2) although immune recovery occurs almost simultaneously with HCMV infection in children receiving unmanipulated HSCT, it is delayed in those receiving a T celldepleted graft; (3) in the study population, the time to development of HCMV-specific T cells correlates with the residual T cell number in the graft and, possibly, with patient age, and (4) steroid treatment for GVHD may favor HCMV reactivation, even after specific T cell reconstitution has occurred. HCMV was rarely detected in the blood of patients who had not previously experienced viral infection; this finding confirms that transmission of HCMV with HSCTs from seropositive donors is an infrequent event, as is also shown in the murine model [29] . As a consequence, HCMV-specific T cell immunity rarely develops after HSCT in the absence of a previous exposure to the virus (2 of 25 HCMV-seronegative patients in the present study), because HCMV infection is required for generation and/or maintenance of the HCMV-specific T cell pool [17, 30] . In this respect, it must be emphasized that determination of HCMV serologic status before transplantation may provide unreliable results, particularly in the presence of low HCMVspecific IgG levels. In fact, passive IgG administration with blood products or immunoglobulin infusions may result in false HCMV seropositivity. This event was observed in 9 of 32 HCMV-seropositive children showing weak neutralizing activity on endothelial cells only. As recently observed by our group, all healthy subjects with previous HCMV infection display serum neutralizing activity on both cell types [26] . The validity of this approach was indirectly confirmed by the fact that none of ϩ cells) in patients spontaneously controlling the infection (untreated) and in patients receiving preemptive therapy (treated). these 9 patients had HCMV infection or immunity develop during follow-up.
In addition to being the major factor driving specific immune reconstitution, HCMV also appears to promote nonspecific T cell recovery in children receiving a T cell-depleted HSCT, as well as in those receiving an unmanipulated graft [17, 30] , because recovery of total T cells is more robust in patients with pretransplantation HCMV infection. The role of HCMV as a trigger for nonspecific T cell activation has been suggested to contribute to the increased risk for GVHD reported for HCMVseropositive patients [31] [32] [33] [34] . In our cohort of patients, the incidence of GVHD, although slightly higher among HCMVseropositive patients, was not significantly influenced by pretransplantation HCMV infection. However, a significant difference in the occurrence of GVHD may have been missed because of the relatively low incidence of GVHD in this patient population. Moreover, contrary to what has been reported by other studies [34, 35] , TRM was comparable in HCMV-seropositive and HCMV-seronegative patients. This excludes a significant influence of previous HCMV infection, as well as its claimed indirect effects, on the outcome of T cell-depleted HSCT.
HCMV-specific immune reconstitution was delayed in recipients of a T cell-depleted HSCT, compared with recipients of an unmanipulated HSCT. In particular, immune recovery occurred soon after HCMV infection in children receiving an unmanipulated HSCT, whereas, in children receiving a T cell-depleted graft, HCMV-specific T cells appeared, on average, 1-2 months after HCMV infection. During this period, patients have a high risk of developing HCMV disease, if they are not promptly managed with preemptive therapy.
The time to HCMV-specific T cell recovery showed great interindividual differences. In fact, notwithstanding immune reconstitution being delayed in this patient population, more than one-half of the patients (61%) were able to reconstitute HCMVspecific immunity within 3 months, as were the great majority of children who received an unmanipulated graft. We found that a higher number of T cells infused with the graft and, possibly, younger age were factors independently associated with a faster immune recovery. Residual mature T cells transferred with the graft may expand efficiently in the absence of any pharmacologic immunosuppressive therapy. However, the possibility that recipient T cells surviving the conditioning regimen might have a role in sustaining virus-specific immune reconstitution cannot be overlooked [36, 37] . A better thymic function might be responsible for better immune reconstitution in younger children [38] , especially when compared with adult patients, in whom naive thymic emigrants have been reported to appear in the circulation only 6 months after receipt of a T cell-depleted HSCT [39] .
Virus-specific T cells appear to protect against HCMV infection. In fact, after immune reconstitution, HCMV either was no longer detected in blood or led to subclinical self-resolving HCMV reactivation in the great majority of patients. However, in patients receiving high-dose steroid therapy for GVHD, HCMV may still replicate at levels requiring preemptive intervention, despite the presence of specific T cells. This fact was already observed in adult patients receiving HSCT [30] and could be explained by the presence of nonfunctional HCMVspecific T cells in patients receiving high-dose steroid therapy [40] . In addition, it can be hypothesized that steroid treatment affects other T cell functions while preserving IFN-␥ production [41] , suggesting that other markers of T cell activation should be investigated to better define the failure of reconstituting T cell immunity during GVHD treatment.
In conclusion, the results of the present study indicate that, also in children receiving a T cell-depleted HSCT from an HLAhaploidentical relative, HCMV seropositivity before transplantation is the main factor conditioning HCMV infection after transplantation and the subsequent reconstitution of virusspecific T cell immunity. In these patients, immune recovery is delayed with respect to the appearance of HCMV in blood, contrary to what is observed in patients receiving an unmanipulated graft. However, the time to HCMV-specific T cell reconstitution is variable among patients and appears to be correlated with the residual T cell number in the graft. Routine immunologic monitoring helps to discriminate, among patients receiving a T celldepleted HSCT, those individuals with more timely HCMVspecific T cell reconstitution and control of viral infection from individuals requiring more-frequent and sustained virologic monitoring, when making the decision regarding antiviral preemptive therapy. In patients with delayed immune reconstitution, adoptive transfer of donor-derived T cells could be of help in facilitating virus-specific T cell recovery [42] .
